See site for story
Ladenburg Thalmann upgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Neutral to Buy, new price target of $3.00.
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $1.45 yesterday, with a 52 week range of $1.28-$5.55.
What? Target to $5, then you say it is new target to $3 , and yesterday's closing price of 1.45. GET YOUR FACT RIGHT before posting trash
Gutsy call to make just prior to trial results coming out. Good sign.
Sentiment: Strong Buy